Table 3.
Summary of recent adjuvant trials
| Trial | Regimen of adjuvant therapy | Median OS (mo) | 1-Year survival (%) | 2-Year survival (%) | 3-Year survival (%) | 5-Year survival (%) |
|---|---|---|---|---|---|---|
| GITSG [27] | RT/FU | 21 | - | 43 | - | 19 |
| EORTC [9] | RT/FU | 17.1 | - | 34 | - | - |
| ESPAC-1 [5] | CCRT/FU | 15.9 | - | 29 | - | 13 |
| CCRT/FU+FL | 19.9 | - | - | - | 10 | |
| CONKO-001 [10] | Gemcitabine | 22.1 | 72.5 | 47.5 | 34 | 22.5 |
| RTOG 97-04 [4] | Gemcitabine+CCRT/FU+gemcitabine | 20.5 | - | - | 31 | - |
| ESPAC-3 [28] | Gemcitabine | 23.6 | 80.1 | 49.1 | - | - |
| FL | 23 | 78.5 | 48.1 | - | - | |
| JASPAC-01 [8] | S-1 | - | - | 59.7 | - | 44.1 |
| Gemcitabine | - | - | 38.8 | - | 24.4 | |
| PRODIGE [13] | Modified FOLFIRINOX | 54.4 | - | - | 63.4 | - |
| Gemcitabine | 35.0 | - | - | 48.6 | - | |
| ESPAC-4 [7] | Gemcitabine/Capecitabine | 28.0 | 84.1 | 53.8 | - | - |
| Gemcitabine | 25.5 | 80.5 | 52.1 | - | - | |
| APACT [14] | Nab-paclitaxel/Gemcitabine | 40.5 | - | - | - | - |
| Gemcitabine | 36.2 | - | - | - | - | |
| Present study | GP+CCRT/gemcitabine+gemcitabine | 33.0 | 91.6 | 63.5 | 47.0 | - |
CCRT, concurrent chemoradiotherapy; FL, fluorouracil and leucovorin; FU, fluorouracil; GP, gemcitabine 1,000 mg/m2 on days 1 and 8 and cisplatin 60 mg/m2 on day 1 repeated every 3 weeks; OS, overall survival; RT, radiotherapy.